Healthcare Services

Advancements in neuroendocrine tumor detection are driving the carcinoid tumor market

April 20, 2026April 20, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Are The Market Size Estimates For The Carcinoid Tumor Market In 2026 And 2030?

The carcinoid tumor market has shown rapid expansion in recent years. It is projected to increase from $1.77 billion in 2025 to $1.96 billion in 2026, maintaining a compound annual growth rate (CAGR) of 10.5%. The historical rise can be linked to factors such as enhanced awareness of rare cancers, the growth of oncology care facilities, the accessibility of somatostatin analog therapies, the establishment of cancer specialty clinics, and progress in neuroendocrine tumor research.

The carcinoid tumor market is projected to experience swift expansion over the coming years, with its value anticipated to reach $2.88 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.1%. This projected growth during the forecast period is fueled by factors such as the increasing creation of new targeted therapies, greater investments in research for rare cancer treatments, the broadening of precision oncology methods, wider acceptance of individualized treatment strategies, and an enhanced emphasis on patient quality-of-life results. Key trends observed during this period will encompass the rising uptake of targeted neuroendocrine tumor treatments, increased application of combination drug therapies, a heightened focus on detecting tumors early, the proliferation of specialized oncology treatment facilities, and a stronger commitment to sustained disease management.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/carcinoid-tumor-global-market-report

Which Primary Drivers Are Impacting The Carcinoid Tumor Market Growth?

The increasing obese population is projected to drive the expansion of the carcinoid tumor market moving forward. The obese population refers to individuals with a body mass index (BMI) of 30 or higher, which indicates an excessive amount of body fat. The rise in the obese population is attributed to elements such as poor nutritional habits, a lack of physical activity, sedentary lifestyles, and greater consumption of processed and high-calorie foods. Obesity contributes to the development of carcinoid tumors by fostering chronic inflammation, insulin resistance, and the increased secretion of growth factors that support tumor proliferation. For instance, in May 2025, according to the Office for Health Improvement and Disparities (OHID), a UK-government agency, it was estimated that about 64.5% of adults (18+) in England were either overweight or living with obesity in 2023–2024, a slight increase from 64.0% in the preceding period (2022–2023). Thus, the growing obese population is stimulating the growth of the carcinoid tumor market.

How Is The Carcinoid Tumor Market Broken Down By Segment Categories?

The carcinoid tumor market covered in this report is segmented –

1) By Disease Type: Gastrointestinal Neuroendocrine Tumor, Pancreatic Neuroendocrine Tumor, Lung Neuroendocrine Tumor, Other Disease Types

2) By Treatment: Octreotide, Lanreotide, Telotristat ethyl, Capecitabine (Xeloda), 5-Fluorouracil (5-FU), Doxorubicin (Adriamycin), Etoposide (VP-16), Dacarbazine (DTIC), Streptozocin, Other Treatments

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By End User: Hospital And Clinics, Academic Institutions, Research Organizations

Subsegments:

1) By Gastrointestinal Neuroendocrine Tumor: Small Bowel Neuroendocrine Tumors, Colorectal Neuroendocrine Tumors, Appendiceal Neuroendocrine Tumors

2) By Pancreatic Neuroendocrine Tumor: Insulinoma, Non-insulinoma, Glucagonoma

3) By Lung Neuroendocrine Tumor: Typical Carcinoid Tumors, Atypical Carcinoid Tumors

4) By Other Disease Types: Thymic Neuroendocrine Tumors, Ovarian Neuroendocrine Tumors

Which Trends Are Shaping Growth In The Carcinoid Tumor Market?

Major companies operating in the carcinoid tumor market are prioritizing developments in diagnostic technologies, especially the fully automated chromogranin A test, with the aim of improving early detection and treatment outcomes. This automated chromogranin A (CgA) test is a diagnostic instrument designed to automatically measure levels of chromogranin A, a biomarker frequently linked to neuroendocrine tumors, including carcinoid tumors. For instance, in October 2023, Thermo Fisher Scientific Inc., a US-based biotechnology research company, received FDA clearance for its Thermo Scientific B·R·A·H·M·S CgA II KRYPTOR immunoassay. This milestone signifies the first FDA-approved Chromogranin A (CgA) test and is currently the only automated immunoassay globally available for monitoring tumor progression in gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients. The assay, which is intended to measure CgA concentration in human serum, empowers laboratories and cancer centers to track tumor growth and evaluate treatment efficacy. By substituting manual laboratory-developed tests, it significantly enhances lab efficiency and ensures more transparent result interpretation. The test utilizes the Thermo Scientific B·R·A·H·M·S KRYPTOR compact PLUS random-access immunoassay analyzer, leveraging TRACE technology to deliver precise results in under 30 minutes.

Which Players Are Present In The Carcinoid Tumor Market Space?

Major companies operating in the carcinoid tumor market are Novartis AG, Ipsen SA, Pfizer Inc, Merck & Co Inc, F Hoffmann-La Roche Ltd, Eli Lilly and Company, Sanofi SA, AstraZeneca PLC, Bristol Myers Squibb, Amgen Inc, Takeda Pharmaceutical Company, Bayer AG, Exelixis Inc, Lexicon Pharmaceuticals Inc, HUTCHMED, Crinetics Pharmaceuticals, Clovis Oncology, Taiho Pharmaceutical, Eisai Co Ltd, Teva Pharmaceutical Industries

Get The Full Carcinoid Tumor Market Report:

https://www.thebusinessresearchcompany.com/report/carcinoid-tumor-global-market-report

Which Region Holds The Highest Market Share In The Carcinoid Tumor Market?

North America was the largest region in the carcinoid tumor market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the carcinoid tumor market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Carcinoid Tumor Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/carcinoid-tumor-global-market-report

Browse Through More Reports Similar to the Global Carcinoid Tumor Market 2026, By The Business Research Company

Desmoid Tumors Market Report 2026

https://www.thebusinessresearchcompany.com/report/desmoid-tumors-global-market-report

Carcinoembryonic Antigen Market Report 2026

https://www.thebusinessresearchcompany.com/report/carcinoembryonic-antigen-global-market-report

Basal Cell Carcinoma Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/basal-cell-carcinoma-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795